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Abstract Genetic diseases associated with an enzyme deficiency 
frequently have reduced intracellular levels of the mutant protein, 
despite apparently normal levels of message and protein 
synthesis. It has been suggested that the endoplasmic reticulum 
(ER) can recognise mutant protein as incorrectly folded and 
invoke 'quality control' processes which cause the retention and 
degradation of this protein. This process may occur, even for 
mutations which do not abrogate protein activity, contributing 
directly to pathophysiology. Genetic diseases associated with 
defects in £R and Golgi processing proteins have also been 
reported and generally result in impaired processing of multiple 
protein products. In this review the role of the ER and Golgi in 
the pathogenesis of genetic diseases relating to the vacuolar 
network are discussed. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction and definitions 
The endoplasmic reticulum (ER) has evolved as a separate 
cellular compartment to provide the selective environment 
required to mediate complex protein folding and modification 
reactions. Two components of the ER have been recognised: 
(1) the rough ER which is usually in close proximity to the 
nucleus and has a functional role in the synthesis, folding and 
post-translational modification of polypeptides [1]; (2) the 
smooth ER which may extend to the cell periphery, has a 
role in calcium sequestration and may be involved in protein 
degradation [2]. In this review the general term ER has been 
used as some of the processing proteins and events described 
have yet to be specifically localised to one or other of these 
compartments. 
Within the lumen of the ER, a range of molecular chaper-
ones (a term used here to describe proteins which bind tran-
siently to newly synthesised protein and may be involved in 
protein folding, oligomerisation and quality control reactions) 
are involved in the folding and post-translational modification 
of newly synthesised polypeptide. These interactions serve not 
only to correctly fold and modify the nascent polypeptide to 
form its correct secondary (hydrogen-bond interactions which 
form a-helices and ^-sheets or covalent disulfide intrachain link-
ages), tertiary {domains and subunits) and quaternary (as-
sembled subunits) structure, but are also thought to anchor 
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the incoming polypeptide chain within the ER lumen and 
may physically drive the translocation process via ATP de-
pendent hydrolysis. Molecular chaperones also act to prevent 
the formation of incorrect intermediates or inappropriately 
folded protein products. 
The Golgi also plays an important role in protein proc-
essing, modifying N-linked oligosaccharide structures at-
tached in the ER, orchestrating O-glycosylation and generat-
ing the targeting signals which control protein traffic in 
the vacuolar network (vacuolar network refers to membrane 
bound intracellular organelles, which include the ER, Golgi, 
carrier vesicles, endosomes and lysosomes). The Golgi ap-
paratus is centrally located in many cells and is compart-
mentalised into membranous stacks called cisternae, which 
allow the separation of specialised processing events. There 
is vesicular transport between Golgi cisternae and protein 
traffic generally proceeds from the eis- to the trans-Go\g\ 
where the control of protein targeting is mediated into either 
the secretory pathway or the distal elements of the vacuolar 
network. 
2. Molecular chaperones of the ER 
A brief description of some typical ER proteins involved in 
polypeptide folding follows (Table 1). 
2.1. Immunoglobulin heavy chain binding protein 
(BiP)IGlucose regulated protein 78 (GRP78) 
BÍP/GRP78 is one of the most abundant and probably best 
characterised of the proteins in the ER lumen [3]. BÍP/GRP78 
is a member of the heat shock protein 70 (Hsp70) family of 
proteins, but is distinguished by an ER targeting signal pep-
tide which allows translocation into the ER membrane and a 
KDEL ER localisation signal to prevent trafficking beyond 
the salvage compartment [4]. BÍP/GRP78 has been postulated 
to interact transiently with a wide range of polypeptides by 
binding a hydrophobic motif, which is part of the globular 
core domain of many proteins [5]. BÍP/GRP78 probably me-
diates folding by interacting with this motif and through its 
capacity to hydrolyse ATP. BÍP/GRP78 has also been re-
ported to bind selectively to incorrectly folded protein (Fig. 
1 [6]). 
2.2. Glucose regulated protein 94 (GRP94) 
GRP94, also known as endoplasmin, is a member of the 
heat shock protein 90 (HSP90) family of proteins. Like BiP/ 
GRP78, GRP94 is abundant, has a KDEL retention signal, 
and possesses Mg2+-dependent ATPase activity [7]. The co-
association and sequential action of BÍP/GRP78 and GRP94 
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have been reported during protein folding [8,9]. 
2.3. Protein disulphide-isomerase (PDI)IERp59 
A critical step in the generation of protein secondary struc-
ture is the formation of disulphide bonds between reactive 
cysteine residues in folding polypeptides. PDI appears to 
have two thioredoxin-like CXXC motifs which function as 
active sites (where C is cysteine and X is any amino acid 
[10]) and the action of PDI is highly dependent on the redox 
conditions in the ER lumen. Alkylation of these active site 
thiols abrogates PDI's isomerase activity but does not affect 
its molecular chaperone capacity [10]. Like BÍP/GRP78 and 
GRP94, PDI can bind and hydrolyse ATP and has been 
shown to associate with mutant protein. 
2.4. Calnexin (p88, IP90) 
Calnexin and calreticulin are lectin-like ER molecular chap-
erones which interact with N-linked oligosaccharides on fold-
ing polypeptides [11,12]. Both calnexin and calreticulin react 
specifically with the mono-glucosylated N-linked high man-
nose oligosaccharides in the ER. Mono-glucosylated high 
mannose oligosaccharides can be re-glucosylated in the ER 
to produce alternating cycles of glucosylation and trimming 
[12]. This may be required for organising the attachment of 
calnexin/calreticulin and is one explanation of how processing 
steps requiring the ordered sequential interaction of molecular 
chaperones may occur. The sequential interaction of BiP/ 
GRP78 and calnexin has been demonstrated [13]. 
3. Protein processing in the Golgi 
In this review the discussion of Golgi processing has been 
restricted to the modification of N-linked oligosaccharides on 
glycoproteins. 
Phosphorylation of high mannose oligosaccharides in the 
Golgi is an important modification as it determines the target-
ing of soluble lysosomal proteins in the vacuolar network 
actively avoiding the default secretory pathway. N-acetylglu-
cosamine-1-phosphotransferase acts in the cw-Golgi to form 
the targeting structures which are the prerequisite for interac-
tion with the rrawi-Golgi localised mannose-6-phosphate re-
ceptors, which direct protein into the endosome-lysosome 
pathway [14,15]. /V-Acetylglucosamine-l-phosphotransferase 
attaches an TV-acetylglucosamine-1 -phosphate residue on to 
acceptor mannose residues in N-linked mannose oligosaccha-
ride tree structures. The removal of the iV-acetylglucosamine 
by a-iV-acetylglucosminyl phosphodiesterase reveals the 
mannose-6-phosphate residues which are involved in lysoso-
mal enzyme targeting. Inability to form mannose-6-phos-
phate residues or to interact with the mannose-6-phosphate 
receptor results in the extracellular secretion of lysosomal en-
zymes. 
N-linked high mannose oligosaccharides attached in the ER 
can be processed down by a-mannosidases in the c«-Golgi 
[16]. Depending on the processing this allows the formation 
of either different types of high mannose oligosaccharides, or 
prerequisites for the formation of complex and hybrid oligo-
saccharides. To form complex and hybrid oligosaccharides 
N-acetylglucosaminyltransferase acts in the medial-Golgi to 
catalyse the attachment of /V-acetylglucosamine to the man-
noses on N-linked oligosaccharides. This structure may be 
further modified in the fraws-Golgi by galactosyltransferase 
and sialyltransferase to attach terminal galactose and sialic 
acid residues. 
4. The folding process and quality control 
The cotranslation-translocation process proceeds at a rate 
of 4-5 amino acid residues per second, allowing complete 
chain elongation in the order of 0.5-2 min for most proteins. 
While the molten globular state can be achieved in the order 
of milliseconds for some proteins, the post translational mod-
ification and additional folding reactions can take several min-
utes. Thus, the extent of protein folding at the point of chain 
termination will depend on the size of the protein, the domain 
structure and its complexity, the presence of membrane span-
ning domains and the degree of post translational modifica-
tion required. 
Partially folded protein intermediates may be continuously 
bound and released by different molecular chaperones until 
the polypeptide has reached the completed stage, involving 
the sequential action of molecular chaperones. The hydrolysis 
Table 1 
ER molecular chaperones 
Molecular chaperone 
Ig heavy chain binding 
protein/ 
Glucose regulated protein 
78 
Glucose regulated protein 
4/ 
Endoplasmin 
Protein disulphide 
isomerase 
Peptidyl-prolyl cis-trans 
isomerase 
Calnexin 
Eponym 
BÍP/GRP78 
GRP94 
PDI 
PPIase/CyPB 
p88/IP90 
Molecular 
weight 
(kDa) 
78 
94 
59/61 
23 
88, 90 
Er retention signal 
KDEL 
KDEL 
KDEL 
VEKPFAIKE 
type I integral 
membrane protein 
Protein recognition 
site 
Hydrophobie motif 
Peptide? 
Cysteine motif 
Proline peptide bond 
Glucose on N-linked 
high mannose 
Protein 
family 
HSP70 
HSP90 
Thioredoxin 
Cyclophilin 
Lectin 
Purported function 
Chaperonerol 
Folding quality con-
trol 
Chaperone 
Folding quality con-
trol 
Isomerase 
Chaperone 
Quality control 
Folding 
Peptide bond isomer-
isation 
Chaperone 
Folding quality con-
trol 
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Fig. 1. Some possible scenarios for protein folding, (a) Normally folded protein with stable domain structure, (b) Mutant protein with exposed 
core domain. BÍP/GRP78 interacts with the mutant protein which has achieved a stable but incorrect conformation. ATP hydrolysis and release 
of the polypeptide is not achieved, (c) Mutant protein which fails to fold. BÍP/GRP78 interacts with and retains the mutant protein, which can 
not achieve a stable conformation and is not released by ATP hydrolysis. 
of A T P may drive this process, pushing the polypeptide to-
wards an appropriate conformation and in the process releas-
ing the folding intermediate for further modification by other 
molecular chaperones. 
The folding process is not 100% efficient and some polypep-
tides will not achieve correct folding, particularly where the 
Table 2 
Genetic diseases in which protein folding/processing have been implicated in pathophysiology 
Defective protein Chaperone/processing protein involved Disease 
(a) Mutant processing proteins 
Sulphatases [ER (1), L (8)] 
Steroids, estrogen [membrane, M] 
Glycoproteins [M] 
Glycoproteins [M] 
Lysosomal enzymes [L] 
Proteoglycan [EM] 
Proteoglycan [EM] 
Glycoproteins [M] 
Phospholipid [M] 
Proteoglycan [EM] 
ER, Not identified 
ER, Steroid sulphatase 
Cytoplasmic, Phosphomannomutase 
Golgi, JV-acetylglucosaminyltransferase II 
Golgi, JV-acetylglucosamine-1 -phospho-
transferase 
Golgi, ß-1,3-galactosyltransferase 
Golgi? 
Golgi, oc-mannosidase II 
Golgi, phosphatidyl inositol 5-phosphatase 
Golgi, ß-1,4-galactosyltransferase 
(b) Mutant proteins interacting with the normal processing machinery 
α-L-Iduronidase [L] 
iV-Acetylgalactosamine-4-sulphatase [L] 
ß-D-Glucuronidase [L] 
rx-D-Glucosidase [L] 
ß-Hexosaminidase A [L] 
ß-Hexosaminidase B [L] 
Glucocerebrosidase [L] 
Aspartylglucosaminidase [L] 
LDL-receptor [CS] 
CFTR [CS] 
Insulin receptor [CS] 
α-1-procollagen [EM] 
Fibrillin [EM] 
α-1-Antitrypsin [S] 
Lipoprotein lipase [M] 
BÍP/GRP78 
BÍP/GRP78 
? 
? 
1 
? 
? 
? 
1 
? 
? 
Calnexin, HSP 70 
? 
BÍP/GRP78 
? 
? 
Multiple sulphatase deficiency 
X-Linked ichthyosis 
Carbohydrate deficient glycoprotein syndrome I 
Carbohydrate deficient glycoprotein syndrome 
II 
I-cell disease (Mucolipidosis II) 
Tn syndrome 
Polycystic kidney disease 
HEMPAS, CDAII 
Lowe syndrome 
Progeroid syndrome 
Mucopolysaccharidosis I (MPS I) 
Mucopolysaccharidosis VI (MPS VI) 
Mucopolysaccharidosis VII (MPS VII) 
Pompe 
Tay-Sachs 
Sandhoff 
Gaucher 
Aspartylglucosamiuria 
Familial hypercholesterolemia 
Cystic fibrosis 
Leprechaunism 
Osteogenesis imperfecta 
Marfan syndrome 
α-1-Antitrypsin deficiency 
Atherosclerosis 
Normal protein localisations are shown in square brackets, and are ER, endoplasmic reticulum; L, lysosomal; M, multiple cellular and extra-
cellular localisation; CS, cell surface and EM, extracellular matrix. ? indicates ER retention and or misfolding has been detected but the molecular 
chaperone involved has not been identified. 
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cell is under conditions of stress or where mutations have been 
introduced into the polypeptide. The ER has developed a 
'quality control' process which actively retains and degrades 
incompletely folded intermediates, unassembled polypeptides, 
aggregated intermediates and misfolded polypeptides [17]. 
This is an important process as it is essential to avoid the 
export of protein aggregates into the cell and to prevent struc-
turally altered and therefore potentially functionally altered 
proteins from entering the cellular machinery. The inability 
to achieve correct conformation may not allow the ATP-de-
pendent release of the polypeptide from its molecular chaper-
one, effectively retaining it in the ER (Fig. 1). Calnexin [11], 
BÍP/GRP78 [13], and PDI [18] have been implicated as part of 
the 'quality control' process in the ER. The mechanism for the 
degradation of misfolded protein appears to be non-lysosomal 
and may involve the cytoplasmic proteasomal degradation 
system, or a related system which is in close proximity to 
the ER [19,20]. 
5. Genetic diseases involving protein processing 
To determine the importance of processing events as a 
mechanism contributing to the pathogenesis of genetic dis-
ease, examples of mutant proteins synthesised in and or traf-
ficking via the vacuolar network, will be outlined (Table 2). 
Two different groups of gene mutations are described, the first 
involving mutant processing proteins and the second involving 
mutant protein interacting with the normal processing ma-
chinery. 
5.1. Mutant processing proteins 
5.1.1. Mutant processing proteins in the ER. Relatively few 
genetic diseases have been attributed to mutations in genes 
coding for molecular chaperones. This could be explained 
by molecular chaperones having domain structures which 
tend to resist the effects of mutation. However, in vitro muta-
genesis studies indicate that mutations causing altered func-
tion in these molecules may be lethal [21,22]. Moreover, cell 
lines expressing BÍP/GRP78 point mutations have been re-
ported to result in the disruption of the structure of the ER, 
with marked vacuolation [23]. These observations are not un-
expected, as many of the processing proteins in the ER exhibit 
multi-functionality and would be expected to affect the proc-
essing of a large number of proteins. 
However, there are some reports of diseases arising from 
gene defects which produce mutant ER processing proteins. 
Recently, multiple sulphatase deficiency (clinical presentation 
similar to the lysosomal storage disorders described below) in 
which a range of lysosomal sulphatases and a microsomal 
sulphatase (steroid sulphatase) have reduced activity, a com-
mon processing event has been implicated in the disease proc-
ess. The modification of a critical cysteine residue, which is in 
a motif conserved in sulphatases, has been postulated to occur 
in the ER and is required to generate active sulphatases [24]. 
X-linked ichthyosis, which is one of a group of cornification 
disorders results from mutations in the gene coding for the 
microsomal enzyme steroid sulphatase [25]. Clinically X-
linked ichthyosis patients present with generalised scaling 
and histologically by hyperkeratosis. Steroid sulphatase is a 
membrane associated microsomal protein and is an important 
enzyme in the processing of steroid sulphate precursors (e.g. 
estrogen synthesis). 
Both of the latter ER proteins affect the processing of mul-
tiple protein products. Genetic diseases arising from muta-
tions in genes coding for molecular chaperones like BiP/ 
GRP78 and PDI have yet to be identified, but this may be 
because they are incompatible with life. 
5.1.2. Mutant processing proteins in the Golgi. A defi-
ciency in ./V-acetylglucosamine-1-phosphotransferase causes 
the disorder known as I-cell disease [26], which affects the 
targeting of lysosomal proteins, resulting in their extracellular 
secretion and causing the lysosomal accumulation of glyco-
saminoglycan, which can not be degraded. Clinical symptoms 
of this disorder resemble that of the lysosomal storage disor-
ders which are described below. A number of lysosomal pro-
teins are inappropriately processed in I-cell disease, which 
seems to be typical of defects in processing proteins. This is 
also observed for several other genetic diseases affecting the 
assembly and Golgi processing of N-linked oligosaccharide 
structures (Table 2). 
5.2. Mutant protein interacting with the normal processing 
machinery 
5.2.1. Mutant lysosomal proteins. The lysosome is a speci-
alised organelle involved in the degradation of complex mac-
romolecules. A genetic disease affecting one of the specific 
enzymes involved in catalysing degradation in the lysosome, 
results in a lysosomal storage disorder by causing the lysoso-
mal accumulation of the partially degraded substrate, which is 
normally catabolised by the specific lysosomal enzyme. Lyso-
somal storage disorders occur with a combined frequency of 
approximately 1:5000 live births and usually result in very 
severe clinical presentation, which may include dwarfism, skel-
etal malformation, hepatosplenomegaly, stiff joints, corneal 
clouding, mental retardation and early death. 
In the lysosomal storage disease Mucopolysaccharidosis 
type I (MPS I), most patient fibroblast cell lines only contain 
low levels of α-L-iduronidase protein [27]. In general, the level 
of enzyme catalytic capacity {ability to turn over substrate) 
correlates with both the lowered intracellular level of protein 
and the patients clinical phenotype, suggesting that if normal 
levels of protein were present then the disease state would be 
averted. The targeted disruption of GRP94 mRNA resulted in 
reduced induction and synthesis of both GRP94 and BiP/ 
GRP78 and caused a six fold reduction in the synthesis of 
recombinant human ot-L-iduronidase [28], suggesting that 
these molecular chaperones are involved in ot-L-iduronidase 
protein processing. 
In fibroblasts from Mucopolysaccharidosis type VI (MPS 
VI) patients, another lysosomal storage disorder, the lysoso-
mal enzyme /V-acetylgalactosamine 4-sulphatase (4S) is re-
duced in activity to less than 5% of normal controls [27,29]. 
This correlates with a reduced level of 4S protein, which ap-
pears to be conformationally altered when studied by a panel 
of monoclonal antibodies [29]. The correlation of residual 4S 
protein, to 4S activity, to patient clinical phenotype, implies 
that the major reason for the onset of pathology in MPS VI is 
the reduced protein level. An individual with 5% of normal 
control catalytic capacity presented with no obvious clinical 
signs of MPS VI, suggesting that there is a threshold for 4S 
activity, above which the onset of pathology will be averted 
[29]. 
Paradoxically, processing studies indicate that mutant 4S 
polypeptide is synthesised at comparable levels to that found 
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in normal control cells [30] and that the residual protein de-
tected in MPS VI cells has relatively normal enzyme activity. 
Several studies have provided evidence that an early biosyn-
thetic compartment may be removing the mutant 4S protein, 
presumably due to the observed altered protein conformation 
[30-32]. Brooks et al. [31] demonstrated that a conservative 
C91S site-directed point mutation caused protein inactivation, 
but there was no evidence of a conformation change in the 
protein when assayed using conformation dependent mono-
clonal antibodies and this mutation resulted in normal target-
ing and normal intracellular levels of protein. In contrast, a 
C91T point mutation caused a detectable conformation 
change and resulted in low intracellular levels of 4S protein 
which was detected mainly in microsomes. Similarly, a stop 
codon mutation *534Q, which resulted in the synthesis of 4S 
containing an additional 51 amino acid tail sequence and a 
nine fold increase in 4S specific activity, caused a detectable 
conformation change and low levels of 4S protein in cells [30]. 
In processing studies, this protein was synthesised normally 
but not transported to the fröro-Golgi network and appeared 
to be retained and degraded, in the ER. Thus, despite being 
synthesised normally and being catalytically active, this mu-
tant protein is recognised as conformationally altered by the 
ER 'quality control' system and is degraded, contributing di-
rectly to the development of MPS VI pathology. 
In patients with the lysosomal storage disorder Tay-Sachs 
disease, it has been postulated that only low amounts of ß-
hexosaminidase A (cc-subunit) protein are able to leave the 
ER, contributing to the residual enzyme activity and associ-
ated clinical phenotype [33]. Site-directed mutagenesis of the 
α-subunit of ß-hexosaminidase caused BÍP/GRP78 associa-
tion, with inappropriate disulphide bond and protein aggre-
gate formation [34]. Zokaeem et al. [35] demonstrated that 
mutant ß-hexosaminidase A was not post-translationally 
modified to form mannose-6-phosphate residues, was not pro-
teolytically converted to the mature form and appeared to be 
retained in an early biosynthetic compartment. For ß-hexosa-
minidase A deficiencies (ß-subunit, Sandhoíf disease), Dlott et 
al. [36] demonstrated that residual protein was synthesised 
and reacted with a specific polyclonal antibody against un-
folded polypeptide. This polypeptide was not mannose-6-
phosphorylated, indicating it had not reached the Golgi, 
and was rapidly degraded, presumably in the ER. 
5.2.2. Mutant cell surface membrane proteins. Cystic Fi-
brosis (CF) is an autosomal recessive genetic disease with an 
incidence of approximately 1 in 2500 live births in whites. CF 
patients present mainly with respiratory and gastrointestinal 
tract symptoms which are caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, 
that codes for a plasma membrane localised chloride channel. 
It has been suggested that most cases of CF are caused by 
mutations which interfere with the biosynthetic folding of the 
CFTR protein. For example the common AF508 mutation 
results in CFTR protein synthesis, but the polypeptide does 
not leave the ER [37]. However, functional studies demon-
strate that although retained in the ER the AF508-CFTR 
protein still forms a functional chloride channel [38]. ER re-
tention mechanisms can therefore recognise and retain struc-
turally altered molecules which still have functional capacity, 
contributing directly to the development of a pathological 
state. This is consistent with the findings for the lysosomal 
storage disorders described above. 
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The involvement of protein conformation in the ER reten-
tion of AF508-CFTR protein has been supported by the ob-
servation that glycerol, a protein stabiliser, reverses the mis-
folding phenotype [39]. Similarly, the trafficking of AF508-
CFTR protein has been shown to be temperature sensitive 
[40]. Both of these treatments are presumed to stabilise the 
mutant CFTR protein, allowing what approaches correct 
folding and subsequent traffic of functional AF508-CFTR 
protein to the cell surface. The ER quality control mechanism 
which retains AF508-CFTR protein has been shown to in-
volve calnexin binding [41]. While normal CFTR protein dis-
sociates from calnexin (transient association), the AF508-
CFTR protein remains associated with calnexin and is pre-
sumed to contribute to its intracellular mislocation in the ER. 
The degradation of mutant CFTR protein appears to be by a 
proteasome mediated pathway [19,20]. 
5.2.3. Mutant extracellular matrix and secretory 
proteins. Mutations in the type I collagen gene result in 
the lethal genetic disease osteogenesis imperfecta (Oí). OI 
presents as a soft connective tissue disorder with clinically 
recognisable facial disproportions and concurrent presence 
of osteoporosis and deafness. Mutant procollagen from osteo-
genesis imperfecta cells specifically associates with BÍP/GRP78 
[42]. Procollagen has been shown to co-immunoprecipitate 
with BÍP/GRP78 and appears to be aberrantly folded and 
localised in the ER [42]. However, unlike the other genetic 
diseases discussed, considering the autosomal dominant na-
ture of the disease and the structural effect of mutant collagen, 
it may actually be beneficial to enhance the ER retention and 
degradation of mutant collagen. In the case of structural pro-
teins where mutations in a single alíele result in a disease 
process, the ER may actually reduce the severity of the disease 
by reducing the number of structurally aberrant molecules 
being incorporated into the extracellular matrix. 
Mutations in the gene coding for the complement (Cl) in-
hibitor (which is a serpin or serine protease inhibitor) appear to 
affect the intracellular transport and secretion of the protein, 
resulting in type I hereditary angioedema. Patients present 
clinically with episodes of local swelling, affecting the face, 
extremities, upper airways and gastrointestinal tract. Bio-
chemical and immunofluorescence studies indicate that in af-
fected cells, the mutant protein is localised in the ER and is 
subsequently degraded [43]. Mutations in the carboxyl termi-
nal domain of the Cl inhibitor and other serpins appear to be 
important in determining correct folding, which is necessary 
to avoid ER retention and ensure correct protein folding and 
trafficking [44]. 
6. Mechanism of action of molecular chaperones 
The co-induction in the synthesis of molecular chaperones 
processing polypeptides [45], the identification of complexes 
which contain polypeptide folding intermediates associated 
with different molecular chaperones [46], and the sequential 
action of molecular chaperones on a common substrate [47], 
all suggest that ER processing is a coordinated process. This 
apparent concerted action may function to hold a polypeptide 
in a specific conformation so that it can be appropriately 
modified/processed or simply drive the folding process to-
wards the formation of a particular conformation. Molecular 
chaperones have a role in preventing the aggregation of fold-
ing intermediates and may even be involved in protein disag-
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gregation. It is important to prevent folding domains of differ-
ent polypeptides from interacting during assembly, but it may 
be equally important to keep separate domains within a pro-
tein from interacting. A protein with a complex multi-domain 
structure may therefore have multiple chaperones acting upon 
it simultaneously, coordinating the sequential formation of 
subdomains and eventually condensing the polypeptide into 
a final compact tertiary/quaternary structure [48]. 
The folding process must be continually monitored for mis-
folded polypeptide, a process termed 'quality control' which is 
probably integrally linked to the action of molecular chaper-
ones. The exact molecular mechanisms responsible for the ER 
'quality control' processes are yet to be fully recognised. How-
ever, retention alone is not sufficient to induce the degradation 
of protein by the ER 'quality control' system. The attachment 
of the KDEL ER targeting signal to polypeptides which fold 
correctly therefore results in retention but not degradation of 
the protein. Exposure of buried internal domains of polypep-
tides has been postulated to signal incorrect folding, which is 
detected by molecular chaperones, targeting the protein for 
degradation (Fig. 1, [6]). While exposure of internal domains 
may be a prerequisite signal for retention and degradation, 
the fact that normal folding intermediates may have ex-
posed internal domains during folding, would suggest that 
this is not the only component for the recognition of incorrect 
folding. 
7. The role of protein processing in genetic disease 
Gene mutations which cause genetic disease, must result in 
a structural change in the associated protein. Protein folding 
studies indicate that mutations frequently hinder the final 
stages of protein folding, arresting the process by the forma-
tion of incomplete folding intermediates [49]. In some cases 
these intermediates will have reduced structural stability while 
others may form stable structures which exhibit functional 
properties. In many genetic diseases residual levels of protein 
with at least partial function are detected. It is postulated that 
the majority of polypeptide is retained and or degraded in the 
ER by the 'quality control' system and that the residual pro-
tein levels and function seen in many patients represents the 
small amount of polypeptide which escapes this recognition 
process. This may indicate either inability of the ER to detect 
all intermediates, or the ability of some molecules to achieve 
near normal conformation and thereby evade the ER detec-
tion system. The examples described here (Table 2) and re-
cently by Bychkova and Ptitsyn [49] and Thomas et al. [50] 
support the hypothesis that ER retention and degradation of 
mutant protein contributes to pathophysiology in genetic dis-
ease, but it remains to be determined how wide spread is this 
proposed phenomenon. For diseases like MPS VI the ER 
retention of mutant but partially functional polypeptides 
may be a major factor in the development of patient pathol-
ogy, but this would obviously not be the case for diseases 
where there are a large number of deletion mutations, which 
tend to abrogate protein function. Where ER retention and 
degradation of either partially or fully active mutant protein 
occurs the ER 'quality control' process will contribute to the 
onset of pathology in the patient. Mutations in processing 
proteins can be expected to affect the function of multiple 
protein products and will also result in pathogenesis, but in 
some cases mutations in the processing machinery may be 
incompatible with life. 
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